Sulphite content of Australian pharmaceutical products.
Explore the source record for details and available documents.
Australia↗
Biomedical subjects
R G Challen
Publications and source records attributed to R G Challen.
Gluten content of Australian pharmaceutical products.
The treatment of patients with coeliac disease is based on the strict avoidance of gluten. Such patients may be at risk if they ingest inadvertently pharmaceutical products that contain gluten. This paper provides information on the gluten content of Australian pharmaceutical products. It is recommended that legislation be introduced to require that excipients in pharmaceutical products which are known to be potentially hazardous to susceptible individuals be listed on the product label, possibly in code form.
Australia↗
Labelling of pharmaceutical products.
Explore the source record for details and available documents.
Drug Labeling↗
Postoperative epilepsy: a double-blind trial of phenytoin after craniotomy.
In a double-blind trial of phenytoin for the prevention of postoperative epilepsy in craniotomy patients, epilepsy was observed in 7.9% (8/101) of patients treated with phenytoin and in 16.7% (17/102) of those receiving placebo. Therapeutic drug levels were associated with a significant reduction in the frequency of epilepsy. Three-quarters of the fits occurred within a month of cranial surgery. High rates of epilepsy have been observed after cranial surgery in patients with meningioma, aneurysm, and head injury with or without intracranial clots, and routine prophylaxis with phenytoin would seem to be indicated in such patients.
Clinical Trials as Topic↗